EPISODE · Mar 3, 2026 · 2 MIN
The Clinical and Regulatory Milestone of Zongertinib in First-Line NSCLC
from TheBrief.Health · host TheBrief.Health
FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.
What this episode covers
FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.
NOW PLAYING
The Clinical and Regulatory Milestone of Zongertinib in First-Line NSCLC
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.